ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

9:00AM-11:00AM: Abstract Number: 1167

Transcriptome Analysis of Peripheral Blood Reveals Superiority of the Triple Combination of Baricitinib, Rituximab, and Tacrolimus Therapy (BRT-Tx.) for anti-MDA5 Antibody-positive Dermatomyositis (MDA5-DM)

(1155–1182) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 0961

Transcriptomic Analysis of Scleroderma Monocytes Identifies Distinct Clinically Relevant Clusters and Novel Genes Associated with Disease Complications

(0934–0964) Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1522

Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis

(1513–1533) Systemic Sclerosis & Related Disorders – Clinical Poster II: Clinical Trial, Treatment & Intervention

9:00AM-11:00AM: Abstract Number: 1369

Treatment Patterns and Drivers of Biologic Prescriptions in Patients with Primary Sjögren’s Disease: Results from a Multinational, Real-World Survey

(1365–1382) Sjögren’s Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1549

Treatment Patterns for Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data

(1534–1553) Vasculitis – ANCA-Associated Poster II: Epidemiology, Outcomes, & Classification

9:00AM-11:00AM: Abstract Number: 1182

Treatment Trajectories and Patient Outcomes in Idiopathic Inflammatory Myopathies

(1155–1182) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1489

Treatment with Upadacitinib in Patients with Systemic Lupus Erythematosus Results in the Inhibition of B-Cell–related Biomarkers: Analysis of the M19-130 (SLEek) Phase 2 Study

(1488–1512) SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 0991

Trends in Arthroplasty Utilization for Inflammatory Arthritis Including Rheumatoid Arthritis and Spondyloarthritis in China: Analysis of a Large National Database

(0965–0992) Epidemiology & Public Health Poster II

9:00AM-11:00AM: Abstract Number: 1399

Trends in Proportionate Cardiovascular Mortality in Patients with Ankylosing Spondylitis in the Era of Biologic Therapies: Analysis of US Death Certificate Data

(1383–1411) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Imaging & AS

9:00AM-11:00AM: Abstract Number: 1513

Trends in Systemic Sclerosis- related Mortality by Age, Sex and Race in the United States, 1999-2019

(1513–1533) Systemic Sclerosis & Related Disorders – Clinical Poster II: Clinical Trial, Treatment & Intervention

9:00AM-11:00AM: Abstract Number: 1243

Tubulointerstitial Inflammation Is Associated with End-Stage Renal Disease in Pediatric Lupus Nephritis: A Single Center Retrospective Cohort Study

(1221–1255) Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1149

Tumor Necrosis Factor Inhibitors as First Line Steroid-Sparing Therapy for Neurosarcoidosis: A Case Series

(1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 0969

Tumor Necrosis Factor-α Inhibitors Reduces Obstructive Sleep Apnea in Patients with Juvenile Idiopathic Arthritis: A Population-based Cohort Study

(0965–0992) Epidemiology & Public Health Poster II

9:00AM-11:00AM: Abstract Number: 1045

Ultrasound Findings in Patients with Difficult to Treat Rheumatoid Arthritis

(1033–1051) Imaging of Rheumatic Diseases Poster I

9:00AM-11:00AM: Abstract Number: 1312

Uncovering Risk Factors for Adverse Events and Infections in Rheumatoid Arthritis and Rheumatoid Arthritis with Interstitial Lung Disease Under Biologics or Targeted Synthetic DMARDs: Insights from the KOBIO Registry

(1308–1344) RA – Treatments Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].